{"id":957143,"date":"2026-05-01T08:08:45","date_gmt":"2026-05-01T12:08:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/"},"modified":"2026-05-01T08:08:45","modified_gmt":"2026-05-01T12:08:45","slug":"weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/","title":{"rendered":"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide)"},"content":{"rendered":"

\nThe addition of Ozempic\u00ae pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes
\n<\/h2>\n
\n

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (\u201cWeight Watchers\u201d), the global leader in science-backed weight management, announced that it will begin offering access to Novo Nordisk\u2019s now available\u00a0Ozempic\u00ae <\/sup>pill<\/strong> (semaglutide) through its Med+ offering and affiliated medical groups. The addition will give members a once-daily GLP-1 option for adults living with type 2 diabetes, further expanding Weight Watchers\u2019 growing portfolio of oral GLP-1 treatments available through a clinically supported program designed to help members succeed.<\/p>\n

Novo Nordisk first introduced Ozempic\u00ae<\/sup> in the U.S. as an injectable GLP-1 for adults with type 2 diabetes, and the brand has since become one of the most widely recognized names in the category. The Ozempic\u00ae<\/sup> pill builds on that foundation, offering a once-daily semaglutide option for adults with type 2 diabetes. With widespread insurance coverage of Ozempic, many eligible members can leverage their pharmacy benefits to make monthly prescription costs as low as $25. Weight Watchers supports members as they navigate prior authorization and utilization management requirements in order to help them find the best option whether that be insurance or cash pay.<\/p>\n

\u201cFor adults living with type 2 diabetes, finding comprehensive support is extremely important, including clinical guidance, appropriate medication, insurance navigation and day-to-day tools\u201d said Jon Volkmann, Chief Operations Officer at Weight Watchers. <\/strong>\u201cWith the addition of Ozempic\u00ae<\/sup> pill to our formulary, Weight Watchers Med+ is giving eligible members access to another FDA-approved semaglutide option, supported by clinicians and a care team who can help them navigate insurance and by a broader program designed to support diabetes care in everyday life.\u201d<\/p>\n

The launch reflects Weight Watchers\u2019 continued focus on expanding access to trusted, brand-name GLP-1 medications while pairing treatment with comprehensive support designed for real life. Through Weight Watchers Med+, clinically eligible members will be able to access Ozempic\u00ae<\/sup> pill alongside care from board-certified clinicians, insurance support, and additional tools designed to support the treatment journey. Members also receive access to the Weight Watchers Diabetes Support program, with tailored nutrition guidance for individuals living with diabetes, coaching, virtual and in real life community, and access to a blood sugar tracker to see patterns and changes in blood sugar over time. In a study of 136 individuals, members on the Weight Watchers diabetes nutrition program experienced a 0.75% reduction in HbA1c after 6 months.<\/p>\n

\u201cIf you\u2019re living with type 2 diabetes, having options matters and the newly available, FDA-approved Ozempic\u00ae<\/sup> pill is another way we\u2019re supporting people by offering a choice that fits into their daily routine,\u201d said Ed Cinca, senior vice president of Marketing & Patient Solutions at Novo Nordisk Inc. \u201cPartnering with Weight Watchers helps broaden patient access, with the coaching and clinical support members can lean on to feel confident as they navigate treatment.\u201d<\/p>\n

\n ABOUT WEIGHT WATCHERS<\/strong>
\n
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business\u2019 full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com<\/u><\/a>.<\/p>\n

\n For investor inquiries, please contact:<\/strong>
\n
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com<\/u><\/a><\/p>\n

\n For media inquiries, please contact:<\/strong>
\n
Lizzy Levitan
WW@hunt-gather.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The addition of Ozempic\u00ae pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (\u201cWeight Watchers\u201d), the global leader in science-backed weight management, announced that it will begin offering access to Novo Nordisk\u2019s now available\u00a0Ozempic\u00ae pill (semaglutide) through its Med+ offering and affiliated medical groups. The addition will give members a once-daily GLP-1 option for adults living with type 2 diabetes, further expanding Weight Watchers\u2019 growing portfolio of oral GLP-1 treatments available through a clinically supported program designed to help members succeed. Novo Nordisk first introduced Ozempic\u00ae in the U.S. as an injectable GLP-1 for adults with … <\/p>\n

Continue reading “Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-957143","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nWeight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The addition of Ozempic\u00ae pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (\u201cWeight Watchers\u201d), the global leader in science-backed weight management, announced that it will begin offering access to Novo Nordisk\u2019s now available\u00a0Ozempic\u00ae pill (semaglutide) through its Med+ offering and affiliated medical groups. The addition will give members a once-daily GLP-1 option for adults living with type 2 diabetes, further expanding Weight Watchers\u2019 growing portfolio of oral GLP-1 treatments available through a clinically supported program designed to help members succeed. Novo Nordisk first introduced Ozempic\u00ae in the U.S. as an injectable GLP-1 for adults with … Continue reading "Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-01T12:08:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide)\",\"datePublished\":\"2026-05-01T12:08:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/\"},\"wordCount\":694,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/\",\"name\":\"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM=\",\"datePublished\":\"2026-05-01T12:08:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/","og_locale":"en_US","og_type":"article","og_title":"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide) - Market Newsdesk","og_description":"The addition of Ozempic\u00ae pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (\u201cWeight Watchers\u201d), the global leader in science-backed weight management, announced that it will begin offering access to Novo Nordisk\u2019s now available\u00a0Ozempic\u00ae pill (semaglutide) through its Med+ offering and affiliated medical groups. The addition will give members a once-daily GLP-1 option for adults living with type 2 diabetes, further expanding Weight Watchers\u2019 growing portfolio of oral GLP-1 treatments available through a clinically supported program designed to help members succeed. Novo Nordisk first introduced Ozempic\u00ae in the U.S. as an injectable GLP-1 for adults with … Continue reading \"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-01T12:08:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide)","datePublished":"2026-05-01T12:08:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/"},"wordCount":694,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/","name":"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM=","datePublished":"2026-05-01T12:08:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMTIwMyM3NTc3NjkwIzIwMDUzNTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/weight-watchers-expands-med-with-access-to-new-ozempic-pill-semaglutide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Weight Watchers Expands Med+ With Access to New Ozempic\u00ae pill (semaglutide)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=957143"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957143\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=957143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=957143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=957143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}